论文部分内容阅读
2013年岁末,乙肝疫苗风波再起。12月初以来,连续的婴儿死亡事件将乙肝疫苗安全问题推到了舆论的风口浪尖,引起了全社会对乙肝疫苗的广泛关注,涉事企业深圳康泰生物制品股份有限公司(以下简称“康泰”),也因此陷入了重重质疑中。事件发生以后,国家食品药品监督管理局立即采取相关应急预案。暂停使用出现问题的批次产品,康泰公司也对事件进行回应。但是,不论是哪个环节出了问题,只要关系到人民的生命安全。就是重中之重的大事。虽然国家食品药品监督管理总局、国家卫生计生委
The end of 2013, hepatitis B vaccine crisis resurgence. Since early December, successive infant deaths have pushed the issue of hepatitis B vaccine safety to the cusp of public opinion and aroused widespread concern in the whole society regarding hepatitis B vaccine. The enterprise involved in the study, Shenzhen Kangtai Biological Products Co., Ltd. (hereinafter referred to as “Kangtai”), , And therefore into a lot of questions. After the incident, the State Food and Drug Administration immediately take the relevant contingency plans. Suspend the use of the product in question, Contax also responded to the incident. However, no matter what part of the problem, as long as the relationship between the people’s lives and safety. Is the most important event. Although the State Food and Drug Administration, the National Health and Family Planning Commission